Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

BVS

Bioventus Inc

Last Close
13.32
Oct 30 • 3:59 PM ET Dollar change-1.55 Percentage change(-10.39%)
Aftermarket Close
13.32
Aftermarket • 7:30 PM ET Dollar change-0.01 Percentage change(-0.04%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Medical Devices USA Small NASD
Peers: OFIX ANIK CNMD ZBH ENOV IART XTNT VCEL MDXG SNWV
 | Held by: AVUV IWM VTI VXF IWO DFAS FESM VTWO SCHA DFMC
Scroll to Statements
Index
RUT
Market Cap
1.12B
Enterprise Value
1.40B
Income
54.46M
Sales
581.85M
Book/sh
3.35
Cash/sh
0.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
930
IPO
Feb 11, 2021
P/E
17.18
Forward P/E
14.48
PEG
0.90
P/S
1.93
P/B
3.98
P/C
38.04
P/FCF
11.97
EV/EBITDA
13.16
EV/Sales
2.41
Quick Ratio
1.17
Current Ratio
1.69
Debt/Eq
1.16
LT Debt/Eq
1.05
Option/Short
Yes / Yes
EPS (ttm)
0.78
EPS next Y
0.92
EPS next Q
0.15
EPS this Y
14.54%
EPS next Y
18.17%
EPS next 5Y
16.02%
EPS past 3/5Y
- 33.74%
Sales past 3/5Y
3.52% 12.08%
EPS Y/Y TTM
19765.85%
Sales Y/Y TTM
3.14%
EPS Q/Q
333.92%
Sales Q/Q
3.76%
Earnings
Nov 02 AMC
EPS/Sales Surpr.
1.71% -1.44%
Insider Own
30.83%
Insider Trans
0.00%
Inst Own
60.06%
Inst Trans
6.18%
ROA
7.89%
ROE
27.96%
ROIC
11.61%
Gross Margin
67.82%
Oper. Margin
10.56%
Profit Margin
9.36%
SMA20
-3.62%
SMA50
-2.77%
SMA200
22.23%
Trades
Shs Outstand
68.21M
Shs Float
47.25M
Short Float
6.73%
Short Ratio
5.63
Short Interest
3.18M
52W High
15.89 -16.16%
52W Low
6.47 105.95%
Volatility
5.07% 4.04%
ATR (14)
0.58
RSI (14)
43.98
Beta
0.65
Rel Volume
1.18
Avg Volume
564.49K
Volume
666,725
Perf Week
-10.93%
Perf Month
-0.93%
Perf Quarter
-1.08%
Perf Half Y
31.80%
Perf YTD
79.10%
Perf Year
96.82%
Perf 3Y
276.41%
Perf 5Y
-11.75%
Perf 10Y
-
Recom
1.00
Target Price
17.60
Prev Close
14.87
Price
13.32
Change %
-10.39%
Consensus
Strong Buy
Avg. Price Target
$17.60
Implied Upside
+32.1%
Analysts8incl. previous ratings
Rating Distribution6 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 27, 2026Initiated
CCJS Securities
Market Outperform$14+5.1%
Feb 09, 2026Initiated
BBarrington Research
Outperform$13-2.4%
Jul 07, 2025Initiated
CCantor Fitzgerald
Overweight$12-9.9%
Dec 17, 2024Upgrade
JPM logoJJP Morgan
Underweight → Neutral$12 → $13-2.4%
Dec 07, 2023Upgrade
CCanaccord Genuity
Hold → Buy$7-47.5%
Aug 09, 2023Upgrade
CCraig Hallum
Hold → Buy$4 → $6-55.0%
Nov 22, 2022Downgrade
CCraig Hallum
Buy → Hold
Nov 09, 2022Downgrade
JPM logoJJP Morgan
Overweight → Underweight
Nov 09, 2022Downgrade
CCanaccord Genuity
Buy → Hold$18 → $6-55.0%
Mar 15, 2022Initiated
CCraig Hallum
Buy$30+125.1%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bartholdson John A.DirectorJun 02 '26Option Exercise0.0032,2820111,902Jun 04 05:06 PM
SUTTER MARTIN PDirectorJun 02 '26Option Exercise0.0032,2820117,523Jun 04 04:48 PM
STALNECKER SUSAN MDirectorJun 02 '26Option Exercise0.0032,2820138,239Jun 04 04:47 PM
NOHRA GUY PDirectorJun 02 '26Option Exercise0.0032,2820148,892Jun 04 04:47 PM
NEELS GUIDO JDirectorJun 02 '26Option Exercise0.0032,2820117,523Jun 04 04:47 PM
McMurry-Heath MichelleDirectorJun 02 '26Option Exercise0.0032,282077,279Jun 04 04:47 PM
Ladone Mary KayDirectorJun 02 '26Option Exercise0.0032,2820111,263Jun 04 04:46 PM
HAWKINS WILLIAM ADirectorJun 02 '26Option Exercise0.0039,7890297,640Jun 04 04:46 PM
Cowdy Philip G.DirectorJun 02 '26Option Exercise0.0032,282043,982Jun 04 04:46 PM
Beyer PatDirectorJun 02 '26Option Exercise0.0032,2820108,718Jun 04 04:45 PM
Singleton Mark LeonardSVP & CFOApr 10 '26Option Exercise0.0013,0000182,981Apr 14 06:18 PM
CHURCH KATRINA JSVP & Chief Compliance OfficerApr 10 '26Option Exercise0.004,300066,032Apr 14 06:18 PM
D'Adamio AnthonySVP & General CounselApr 10 '26Option Exercise0.009,9250157,967Apr 14 06:17 PM
Singleton Mark LeonardSVP & CFOMar 20 '26Option Exercise0.0018,6250178,072Mar 24 04:59 PM
Singleton Mark LeonardSVP & CFOMar 13 '26Option Exercise0.0013,5000165,312Mar 17 05:03 PM
CHURCH KATRINA JSVP & Chief Compliance OfficerMar 13 '26Option Exercise0.006,955063,253Mar 17 05:02 PM
D'Adamio AnthonySVP & General CounselMar 13 '26Option Exercise0.0017,6360151,844Mar 17 05:01 PM
Claypoole Robert EPresident and CEOMar 13 '26Option Exercise0.0033,5000150,497Mar 17 05:00 PM
McMurry-Heath MichelleDirectorMar 11 '26Sale8.7912,000105,43944,997Mar 13 05:26 PM
McMurry-Heath MichelleDirectorMar 11 '26Proposed Sale8.8112,000105,720Mar 11 10:47 AM
Singleton Mark LeonardSVP & CFOFeb 15 '26Option Exercise0.0020,1530161,241Feb 18 06:30 PM
CHURCH KATRINA JSVP & Chief Compliance OfficerFeb 15 '26Option Exercise0.004,375059,932Feb 18 06:29 PM
D'Adamio AnthonySVP & General CounselFeb 15 '26Option Exercise0.0012,9800144,396Feb 18 06:28 PM
Claypoole Robert EPresident and CEOJan 09 '26Option Exercise0.0093,7500158,714Jan 13 05:30 PM
NOHRA GUY PDirectorDec 04 '25Sale7.5710,00075,658116,610Dec 08 05:02 PM
NOHRA GUY PDirectorDec 04 '25Proposed Sale7.5710,00075,658Dec 04 01:54 PM
McMurry-Heath MichelleDirectorNov 07 '25Sale7.4217,701131,25556,997Nov 10 05:08 PM
McMurry-Heath MichelleDirectorNov 07 '25Proposed Sale7.4127,000200,041Nov 07 04:14 PM
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
PresidentMr. Robert E. Claypoole
Senior VP & CFOMr. Mark L. Singleton
Senior VPMr. Anthony D'Adamio J.D.
M.B.A.Mr. Mike Crowe B.S.
Vice President of Investor Relations & TreasurerMr. David Crawford
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)